Fresenius Kabi announced the immediate availability in the United States of Methocarbamol Injection, USP in a 100 mg per mL 10 mL vial presentation.
Methocarbamol Injection, USP is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The product is the newest addition to Fresenius Kabi’s broad portfolio of medicines for anesthesia and analgesia.
Fresenius Kabi is a developer, manufacturer and provider of injected and infused medicines in the United States with expertise in producing generic alternatives to more expensive brand-name drugs.
“We are pleased to expand our anesthesia and analgesia portfolio with the introduction of Methocarbamol Injection, a medication that can provide relief for people with acute, painful musculoskeletal conditions,” said John Ducker, president and CEO of Fresenius Kabi USA.